Last reviewed · How we verify
TA-650
TA-650 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
TA-650 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | TA-650 |
|---|---|
| Also known as | Infliximab |
| Sponsor | Tanabe Pharma Corporation |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, TA-650 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis (PHASE3)
- Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis (PHASE3)
- Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis (PHASE3)
- Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease (PHASE3)
- Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD) (PHASE3)
- Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease (PHASE3)
- Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions (PHASE3)
- Minimize Menorrhagia in Women With Von Willebrand Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TA-650 CI brief — competitive landscape report
- TA-650 updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI